These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29580162)

  • 1. Updates in pancreatic cancer: Modest gains and hopeful targets.
    Draper A
    J Oncol Pharm Pract; 2019 Jan; 25(1):101-109. PubMed ID: 29580162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.
    Byrne JD; Jajja MRN; O'Neill AT; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):991-998. PubMed ID: 29603014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.
    Xu X; Wu Q; Wang Z; Zheng S; Ge K; Jia C
    Clin Exp Med; 2019 Feb; 19(1):149-157. PubMed ID: 30498929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
    Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
    Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
    Cinar P; Ko AH
    Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
    Caparello C; Meijer LL; Garajova I; Falcone A; Le Large TY; Funel N; Kazemier G; Peters GJ; Vasile E; Giovannetti E
    World J Gastroenterol; 2016 Aug; 22(31):6987-7005. PubMed ID: 27610011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for resectable and advanced pancreatic cancer.
    Berlin JD; Rothenberg M
    Oncology (Williston Park); 2001 Oct; 15(10):1241-9, 1254; discussion 1254-64. PubMed ID: 11702956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
    Kim R
    Lancet Oncol; 2011 Jan; 12(1):8-9. PubMed ID: 21050812
    [No Abstract]   [Full Text] [Related]  

  • 12. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
    Erstad DJ; Sojoodi M; Taylor MS; Ghoshal S; Razavi AA; Graham-O'Regan KA; Bardeesy N; Ferrone CR; Lanuti M; Caravan P; Tanabe KK; Fuchs BC
    Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29903803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the pharmacological treatment of advanced pancreatic cancer.
    Kulke MH
    Expert Opin Investig Drugs; 2003 Jun; 12(6):983-92. PubMed ID: 12783602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
    Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of systemic therapy for advanced pancreatic cancer.
    El-Rayes BF; Philip PA
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for routine use of adjuvant therapy in pancreatic cancer.
    Kennedy EP; Yeo CJ
    J Surg Oncol; 2007 Jun; 95(7):597-603. PubMed ID: 17230543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
    Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
    World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
    Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
    Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.